| Literature DB >> 30526540 |
E Garcia Del Pozo1, J Collazos2, J A Carton3,4, D Camporro1, V Asensi5,6.
Abstract
BACKGROUND: Osteomyelitis is a difficult-to-cure infection with a high relapse rate despite combined medical and surgical therapies. Some severity factors, duration of antimicrobial therapy and type of surgical procedure might influence osteomyelitis relapse.Entities:
Keywords: Antibiotics; Debridement; Muscular flap; Osteomyelitis; Relapse; Severity factors
Mesh:
Substances:
Year: 2018 PMID: 30526540 PMCID: PMC6286499 DOI: 10.1186/s12879-018-3550-6
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic, clinical, microbiological and therapeutic features of the patients according to the outcome
| Relapse ( | No relapse ( | P | ||
|---|---|---|---|---|
| Gender | Male | 16 (18.6%) | 70 (81.4%) | 0.096 |
| Female | 10 (33.3%) | 20 (66.7%) | ||
| Age | Years | 57.42 (51.13–63.72) | 51.67 (47.93–55.40) | 0.14 |
| Origin/source | Hematogenous | 4 (20.0%) | 16 (80.0%) | 0.5 |
| Post-traumatic | 12 (19.4%) | 50 (80.6%) | ||
| Post-surgical | 10 (29.4%) | 24 (70.6%) | ||
| Bones involved | Femur | 6 (22.2%) | 21 (77.8%) | 0.9 |
| Tibia | 17 (23.6%) | 55 (76.4%) | ||
| Fibula | 1 (16.7%) | 5 (83.3%) | ||
| Humerus | 0 (0%) | 3 (100%) | ||
| Ulna | 1 (20.0%) | 4 (80.0%) | ||
| Radius | 1 (33.3%) | 2 (66.7%) | ||
| Imaging (other than radiographs) | Yes | 20 (28.2%) | 51 (71.8%) | 0.06 |
| No | 6 (13.3%) | 39 (86.7%) | ||
| C Reactive Protein (C-RP) | mg/L | 8.865 (.357–17.373) | 6.440 (4.739–8.1395) | 0.6 |
| Erythrocyte sedimentation rate (ESR) | mm/h | 53.52 (37.26–69.78) | 65.01 (57.20–72.82) | 0.18 |
| Duration of follow-up | Months | 56.12 (37.80–74.43) | 70.28 (58.67–81.89) | 0.24 |
| Severity factors | ||||
| Relapse of previous osteomyelitis | Yes | 14 (28.6%) | 35 (71.4%) | 0.17 |
| No | 12 (17.9%) | 55 (82.1%) | ||
| Symptoms longer than 3 months | Yes | 22 (28.6%) | 55 (71.4%) | 0.025 |
| No | 4 (10.3%) | 35 (89.7%) | ||
| Presence of osteosynthesis material | Yes | 13 (22.0%) | 46 (78.0%) | 0.9 |
| No | 13 (22.8%) | 44 (77.2%) | ||
| Bone exposure | Yes | 12 (26.1%) | 34 (73.9%) | 0.4 |
| No | 14 (20.0%) | 56 (80.0%) | ||
| Vascular involvement | Yes | 5 (45.5%) | 6 (54.5%) | 0.067 |
| No | 21 (20.0%) | 84 (80.0%) | ||
| Diabetes | Yes | 3 (30.0%) | 7 (70.0%) | 0.7 |
| No | 23 (21.7%) | 83 (78.3%) | ||
| Multiresistant/polymicrobial infection | Yes | 12 (23.5%) | 39 (76.5%) | 0.8 |
| No | 14 (21.5%) | 51 (78.5%) | ||
| Immunosuppression | Yes | 2 (50.0%) | 2 (50.0%) | 0.22 |
| No | 24 (21.4%) | 88 (78.6%) | ||
| Presence of severity factors | Yes | 12 (29.3%) | 29 (70.7%) | 0.19 |
| No | 14 (18.7%) | 61 (81.3%) | ||
| Types of severity factors | No | 14 (18.7%) | 61 (81.3%) | 0.4 |
| Local | 5 (22.7%) | 17 (77.3%) | ||
| Systemic | 4 (40.0%) | 6 (60.0%) | ||
| Both | 3 (33.3%) | 6 (66.7%) | ||
| Number of severity factors | 3.19 (2.69–3.69) | 2.49 (2.2–2.76) | 0.02 | |
| Microbiology | ||||
| Gram-positive cocci a | Gram-positive cocci | 17 (24.6%) | 52 (75.4%) | 0.8 |
| Others | 6 (27.3%) | 16 (72.7%) | ||
| Gram-negative bacilli a | Gram-negative bacilli | 9 (28.1%) | 23 (71.9%) | 0.8 |
| Others | 15 (25.4%) | 44 (74.6%) | ||
|
|
| 12 (25.0%) | 36 (75.0%) | 0.9 |
| Others | 8 (23.5%) | 26 (76.5%) | ||
| Gram-pos cocci vs Gram-neg bacilli a | Gram-positive cocci | 14 (25.0%) | 42 (75.0%) | 0.8 |
| Gram-negative bacilli | 6 (27.3%) | 16 (72.7%) | ||
| Treatment | ||||
| Type of treatment | Antibiotics only | 6 (66.7%) | 3 (33.3%) | 0.004 |
| Antibiotics plus surgery | 20 (18.7%) | 87 (81.3%) | ||
| Intravenous beta-lactams | β-lactams | 5 (13.9%) | 31 (86.1%) | 0.7 |
| Other antibiotics | 4 (18.2%) | 18 (81.8%) | ||
| Oral β-lactams | β-lactams | 4 (23.5%) | 13 (76.5%) | 0.7 |
| Other antibiotics | 9 (17.3%) | 43 (82.7%) | ||
| Oral clindamycin | Clindamycin | 3 (10.7%) | 25 (89.3%) | 0.21 |
| Other antibiotics | 11 (22.0%) | 39 (78.0%) | ||
| Oral rifampin | Rifampin | 4 (15.4%) | 22 (84.6%) | 0.8 |
| Other antibiotics | 10 (19.2%) | 42 (80.8%) | ||
| Duration of intravenous antibiotics | Days | 26.44 (23.24–29.64) | 29.33 (27.09–31.58) | 0.21 |
| Total duration of antibiotic treatment | Days | 80.76 (36.05–125.47) | 69.58 (62.66–76.49) | 0.40 |
| Type of surgery | None | 6 (66.7%) | 3 (33.3%) | 0.004 |
| Debridement | 9 (19.6%) | 37 (80.4%) | ||
| Debridement and flap | 11 (18.0%) | 50 (82.0%) | ||
| Removal of osteosynthesis material b | Yes | 8 (19.0%) | 34 (81.0%) | 0.24 |
| No | 4 (36.4%) | 7 (63.6%) | ||
| Type of surgical reconstruction | None | 15 (27.3%) | 40 (72.7%) | 0.6 |
| Free muscle flap | 2 (14.3%) | 12 (85.7%) | ||
| Pedicled muscle flap | 4 (19.0%) | 17 (81.0%) | ||
| Free fasciocutaneous flap | 5 (23.8%) | 16 (76.2%) | ||
| Pedicled fasciocutaneous flap/rotation | 0 (0%) | 5 (100%) | ||
| Surgical reconstruction | Yes (all types of flaps) | 11 (18.0%) | 50 (82.0%) | 0.23 |
| No | 15 (27.3%) | 40 (72.7%) | ||
Values are expressed as mean (95% CI) or n (%) as appropriate
aThe comparisons of microorganisms/antibiotics have been carried out only in the cases in which the bacteria/antibiotic have been identified
bOnly in patients who had osteosynthesis material
Fig. 1Kaplan Meier cumulative survival curves of the eight severity factors for osteomyelitis
Fig. 2Receiver operating characteristic (ROC) curve corresponding to the predictive formula
Variables significantly associated with relapse according to the Cox regression analysis
| HR (95% CI) | P | |
|---|---|---|
| Symptoms longer than 3 months | 4.98 (1.42–17.54) | 0.012 |
| Bone exposure | 12.66 (3.15–49.26) | 0.0003 |
| Type of surgical treatment | < 0.0001 | |
| None vs Debridement | 3.41 (1.12–10.42) | 0.031 |
| None vs Debridement and flap | 33.27 (7.80–141.88) | < 0.0001 |
| Debridement vs Debridement and flap | 9.75 (2.10–45.21) | 0.004 |
Fig. 3Variables independently associated with osteomyelitis relapse in the Cox regression analysis
Comparison of the demographic and clinical characteristics and recurrence factors in clinical studies of osteomyelitis
| Roine [ | Tice [ | Arias [ | Lin [ | Present series | ||
|---|---|---|---|---|---|---|
| No. patients (% males) | 83 (NS) | 454 (65%) | 129 (80.6%) | 108 (75%) | 116 (74.1%) | |
| Age group | Children (mean 6.7 y) | Mostly adults (mean 51 y) | Adults (range 18–91 y) | Mostly adults (median 54 y) | Adults (mean 53 y) | |
| Country | Costa Rica | USA | Colombia | Singapore | Spain | |
| Origin | Hematogenous | Multiple | Multiple | Multiple | Multiple | |
| Post-traumatic (n, %) | 0 (0%) | 409 (90.1%) a | 115 (89.2%) | 42 (38.9%) | 62 (53.4%) | |
| Bones involved | Mostly long bones | Mostly non-long bones | Mostly long bones | Mostly long bones | Only long bones | |
| 41 (49.4%) | 246 (54.2%) | 49 (38.0%) | 42 (38.9%) | 48 (38.1%) | ||
| Diabetes | NS | 173 (38.1%) | 7 (5.4%) | 58 (53.7%) | 10 (8.6%) | |
| Recurrence (n, %) | 5 (6.0%) | 139 (30.6%) | 30 (23.3%) | 40 (37.0%) | 26 (20.6%) | |
| Mean follow-up (months) | 1.5 or 14 c | 28.3 | 12 | 23,4 | 67.1 | |
| Factors associated with recurrence | Microorganisms involved |
|
| No | MRSA | No |
| Antibiotic type | No d | Yes (vancomycin) e | No | NS | No | |
| Antibiotic duration | No d | NS | No | No | No | |
| Age | No d | No (> 70 y) | No | No | No | |
| Diabetes | NS d | Yes | No | No | No | |
| Peripheral vascular disease | NA d | Yes | No | No | No | |
| Long bones | NS d | NS | No | Yes (lower limbs) | No | |
| Fracture | NA d | NS | No | No | No | |
| Symptoms duration | No d | NS | NS | NS | Yes (> 3 months) | |
| Bone exposure | NA d | NS | No | No | Yes | |
| Type of surgery | No d | NS | NS | No | Yes | |
| C-RP | Yes d | NS | NS | No | No | |
| ESR | No d | NS | NS | Yes (≥ 20 mm/h) | No |
NA denotes not applicable, NS not studied, MSSA methicillin-susceptible Staphylococcus aureus, MRSA methicillin-resistant Staphylococcus aureus, C-RP C-reactive protein, ESR erythrocyte sedimentation rate
aDescribed as associated with wounds
bRespect to the total number of patients
cAll patients were followed-up for a mean of at least 1,5 months, and 78% of them for a mean of 14 months
dFactors associated with sequelae (28 patients, 33.7%); data for recurrence are not provided
eOnly in staphylococcal infections